舒洛地特治疗糖尿病肾病蛋白尿临床评价  

Clinical Evaluation of Sulodexide in Treating Proteinuria in Diabetic Nephropathy

作　　者：高丹[1] 吴歌[1] 景三辉[1] 

机构地区：[1]郑州大学第一附属医院肾内科,河南郑州450000

出　　处：《中国药业》2017年第16期65-67,共3页China Pharmaceuticals

摘　　要：目的探讨舒洛地特治疗糖尿病肾病(DN)蛋白尿中的临床疗效。方法选取医院收治出现蛋白尿的糖尿病肾病患者108例,随机分为试验组和常规组,各54例。两组患者均给予基础对症治疗,在此基础上,常规组患者给予缬沙坦治疗,试验组患者在常规组基础上加用舒洛地特。比较两组患者空腹血糖(FBG)、血肌酐(SCr)、血尿素氮(BUN)、24 h尿蛋白定量(24 h UP)、尿白蛋白排泄率(UAER)、尿β_2-微球蛋白(β_2-MG)、血清胱抑素C(Cys-C)、α_1-微球蛋白(α_1-MG)水平。结果治疗后,试验组患者的SCr,α_1-MG,24 h UP,UAER,β_2-MG,Cys-C水平均低于常规组(P<0.05)。结论舒洛地特治疗糖尿病肾病蛋白尿,可显著改善患者的SCr和尿蛋白指标,有利于延缓肾脏病进展,值得临床推广。Objective To investigate the clinical effect of sulodexide in the treatment of proteinuria in diabetic nephropathy（ DN）.Methods Totally 108 patients with DN and proteinuria were selected and randomly divided into the experimental group and the routine group,54 cases in each group. Both groups were given symptomatic treatment. The routine group was treated with valsartan,on this basis,the experimental group was additionally treated with sulodexide. The levels of FBG,SCr,BUN,24 h UP,UAER,β_2-MG,Cys-C andα_1-MG were compared between the two groups. Results After treatment,The levels of SCr,α_1-MG,24 h UP,UAER,β_2-MG and Cys-C in the experimental group were significantly lower than those in the routine group（ P 0. 05）. Conclusion The treatment of proteinuria in DN with sulodexide can significantly improve serum SCr and urine protein,it is conducive to alleviating kidney disease progression and worthy of clinical promotion.

关 键 词：糖尿病肾病 蛋白尿 舒洛地特 临床疗效 

分 类 号：R969.4[医药卫生—药理学] R587.2[医药卫生—药学]